Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

1 day ago · SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third …

CouponFollow Extension

$43
OFF

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

1 week from now

1 day ago · Inhibrx Biosciences (INBX) reported Q3 2024 financial results, showing a net loss of $43.9 million ($2.84 per share) compared to $51.8 million ($4.39 per share) in Q3 2023. The …

stocktitan.net

25%
OFF

Akoya Biosciences Reports Third Quarter 2024 Financial Results

1 week from now

1 day ago · Third Quarter 2024 Financial Results For the third quarter of 2024, revenue was $18.8 million , a 25% year-over-year decrease from $25.2 million in the third quarter of 2023.

nasdaq.com

$43
OFF

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

1 week from now

1 day ago · Net loss was $43.9 million during the third quarter of 2024, or $2.84 per share, basic and diluted, compared to a net loss of $51.8 million during the third quarter of 2023, or $4.39 …

streetinsider.com

$14
OFF

Immuneering Reports Third Quarter 2024 Financial Results And …

1 week from now

2 days ago · Net Loss: Net loss attributable to common stockholders was $14.6 million, or $0.49 per share, for the third quarter ended September 30, 2024, compared to $12.6 million, or …

businessinsider.com

$2
OFF

Enveric Biosciences Reports Third Quarter 2024 Financial And

1 week from now

1 day ago · Net loss attributable to stockholders was $2.1 million for the third quarter ended September 30, 2024, including $0.5 million in net non-cash expense, with a basic and diluted …

nasdaq.com